Please use this identifier to cite or link to this item:
Title: Therapeutic role of nuclear factor erythroid-2 related factor 2 (Nrf2) in liver disorders
Authors: Grewal A.S
Thapa K
Bansal A
Sharma N
Singh S.
Keywords: Acute liver injury
Alcoholic liver disease (ALD)
Non-alcoholic fatty liver disease (NAFLD)
Nuclear erythroid 2-related factor 2 (Nrf2)
Nrf2 activators
Oxidative stress.
Issue Date: 2020
Publisher: Research Journal of Pharmacy and Technology
Abstract: The progression of liver disease involves the most crucial pathogenic events; oxidative stress and inflammation. Nuclear erythroid 2-related factor 2 (Nrf2) has been regarded as the master regulator of gene expression that are involved in cellular protection via exerting antioxidant, cytoprotective and anti-inflammatory effects. Numerous compounds have been tested as Nrf2 activators including natural (resveratrol, epigallocatechin-3 and curcumin) as well as synthetic compounds (bardoxolone methyl, oltipraz and anethole dithiol ethione) that prevent interaction of Nrf2 with Kelch-like ECH-associated protein 1 (Keap1) due to modification in cysteine sulfhydryl groups of Keap1. The current review demonstrates the function of Nrf2 in various liver diseases; acute liver failure, alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD) and also holds recent studies for the identification of novel drug upregulating Nrf2. There is no approved treatment for liver diseases. Currently oltipraz which is an activator of Nrf2 is in Phase III clinical evaluation for NAFLD; more preclinical and clinical evaluation of drugs as Nrf2 activators is still needed to develop a new treatment strategy for liver disorders.
URI: 10.5958/0974-360X.2020.00699.X
Appears in Collections:Journals

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.